BCRX
USDBioCryst Pharmaceuticals Inc. Common Stock
Precio en Tiempo Real
Gráfico de Precios
Métricas Clave
Métricas de Mercado
Apertura
$7.150
Máximo
$7.270
Mínimo
$7.080
Volumen
4.81M
Fundamentos de la Empresa
Capitalización de Mercado
1.5B
Industria
Drug Manufacturers - Specialty & Generic
País
United States
Estadísticas de Negociación
Volumen Promedio
4.39M
Bolsa
NMS
Moneda
USD
Rango de 52 Semanas
Noticias Relacionadas
Needham Maintains Buy on BioCryst Pharma, Lowers Price Target to $18
Needham analyst Serge Belanger maintains BioCryst Pharma with a Buy and lowers the price target from $20 to $18.
BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update
—Q3 2025 ORLADEYO net revenue of $159.1 million (+37 percent y-o-y)— —Q3 2025 operating profit of $29.6 million (+285 percent y-o-y); non-GAAP operating profit of $51.7 million (+107 percent y-o-y); continued
BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts at the Annual Scientific Meeting of the
JMP Securities Maintains Market Outperform on BioCryst Pharma, Raises Price Target to $27
JMP Securities analyst Jonathan Wolleben maintains BioCryst Pharma with a Market Outperform and raises the price target from $17 to $27.
Needham Maintains Buy on BioCryst Pharma, Raises Price Target to $20
Needham analyst Serge Belanger maintains BioCryst Pharma with a Buy and raises the price target from $17 to $20.
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
– Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio – – Solidifies double digit growth trajectory for HAE portfolio over the
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
– Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio – – Solidifies double digit growth trajectory for HAE portfolio over the
Acciones Relacionadas
Mantente Actualizado
Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.